probucol has been researched along with Diabetes Mellitus, Type 1 in 8 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Probucol is a cholesterol-lowering drug, while ursodeoxycholic acid is a hydrophilic bile acid." | 1.48 | Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes. ( Al-Salami, H; Al-Sallami, H; Arfuso, F; Goločorbin-Kon, S; Kovacevic, B; Mikov, M; Mooranian, A; Takechi, R; Zamani, N, 2018) |
| "The probucol-treated M phi induced less marked increase of H2O2 in islet cells in comparison with control M phi." | 1.29 | Antioxidant, probucol, can inhibit the generation of hydrogen peroxide in islet cells induced by macrophages and prevent islet cell destruction in NOD mice. ( Fukuda, M; Ikegami, H; Kawaguchi, Y; Ogihara, T; Sano, T, 1995) |
| "Probucol (1%) was ineffective." | 1.29 | Antioxidant MDL 29,311 prevents diabetes in nonobese diabetic and multiple low-dose STZ-injected mice. ( Dillberger, JE; Heineke, EW; Johnson, MB; Robinson, KM, 1993) |
| "Insulin-dependent diabetes mellitus (IDDM) results from an inflammatory process leading to destruction of the insulin-producing beta cells of the pancreas." | 1.27 | Effect of probucol on development of diabetes mellitus in BB rats. ( Borquaye, S; Drash, AL; Lieberman, I; Rudert, WA; Wang, R, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mooranian, A | 2 |
| Zamani, N | 2 |
| Luna, G | 1 |
| Al-Sallami, H | 2 |
| Mikov, M | 2 |
| Goločorbin-Kon, S | 2 |
| Stojanovic, G | 1 |
| Arfuso, F | 2 |
| Kovacevic, B | 2 |
| Al-Salami, H | 2 |
| Takechi, R | 1 |
| Fukuda, M | 1 |
| Ikegami, H | 1 |
| Kawaguchi, Y | 1 |
| Sano, T | 1 |
| Ogihara, T | 1 |
| Heineke, EW | 1 |
| Johnson, MB | 1 |
| Dillberger, JE | 1 |
| Robinson, KM | 1 |
| Buzzetti, R | 1 |
| Nisticò, L | 1 |
| Osborn, JF | 1 |
| Giovannini, C | 1 |
| Chersi, A | 1 |
| Sorrentino, R | 1 |
| Bagdade, JD | 1 |
| Stein, E | 1 |
| Ritter, MC | 1 |
| Rabinovitch, A | 1 |
| Suarez, WL | 1 |
| Power, RF | 1 |
| Drash, AL | 1 |
| Rudert, WA | 1 |
| Borquaye, S | 1 |
| Wang, R | 1 |
| Lieberman, I | 1 |
1 trial available for probucol and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Probucol normalizes cholesteryl ester transfer in IDDM.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Carrier Proteins; Cholesterol; Cholesterol Ester T | 1995 |
7 other studies available for probucol and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Bile acid-polymer-probucol microparticles: protective effect on pancreatic β-cells and decrease in type 1 diabetes development in a murine model.
Topics: Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug | 2019 |
Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Humans; Insulin-Secreting Cells | 2018 |
Antioxidant, probucol, can inhibit the generation of hydrogen peroxide in islet cells induced by macrophages and prevent islet cell destruction in NOD mice.
Topics: Animals; Antioxidants; Cell Communication; Cell Survival; Cells, Cultured; Diabetes Mellitus, Type 1 | 1995 |
Antioxidant MDL 29,311 prevents diabetes in nonobese diabetic and multiple low-dose STZ-injected mice.
Topics: Aging; Animals; Antioxidants; Atrophy; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mell | 1993 |
HLA-DQA1 and DQB1 gene polymorphisms in type I diabetic patients from central Italy and their use for risk prediction.
Topics: Adolescent; Alleles; Base Sequence; Diabetes Mellitus, Type 1; Female; HLA-DQ alpha-Chains; HLA-DQ A | 1993 |
Combination therapy with an antioxidant and a corticosteroid prevents autoimmune diabetes in NOD mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Blood Glucose; Diabetes Mellitus, Type 1; Disease M | 1992 |
Effect of probucol on development of diabetes mellitus in BB rats.
Topics: Actuarial Analysis; Age Factors; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1 | 1988 |